HEALTH RELATED QUALITY OF LIFE IN LONG TERM SURVIVORS OF LYMPHOMA- A POPULATION BASED STUDY
Author(s)
Blommestein H1, Versteegh M1, Oerlemans S2, Van de Poll-Franse L2, Uyl-de Groot C11Erasmus University, Rotterdam, Netherlands, 2Comprehensive Cancer Centre South, Eindhoven, Netherlands
Presentation Documents
OBJECTIVES: To assess the health related quality of life (HRQoL) in the growing group of long term lymphoma survivors with preference based instruments. METHODS: Population based cross-sectional data was collected in patients diagnosed with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) (N=778). HRQoL was measured using both a generic and a disease specific preference-based instrument, the EQ-5D 5-level and a time-trade-off valued version of the EORTC QLQ-C30. RESULTS: On average patients with HL or NHL were diagnosed 4.35[±SD 2.56] years prior to the study. Mean QoL was 0.83 using EQ-5D [±SD .16, Range -.11 - 1.0] and 0.88 using QLQ-C30 [±SD .10 Range .38 - 1.0]. Mean EQ-5D score for lymphoma survivors is significantly lower than the average HRQoL found in the Dutch population (p<0.001). However, mean QLQ-C30 score for lymphoma survivors did not differ from the Dutch population. Regression analysis identified a significant lower HRQoL with having active disease (measured by treatment activity) and comorbidities depression, high blood pressure, respiratory diseases, osteoarthritis, and back-pain. Age, type of lymphoma, and time passed since diagnosis did not affect HRQoL. The discrepancy between EQ-5D and QLQ-C30 in deviation from the Dutch population is likely to be caused by better discrimination of worse health states in the EQ-5D. CONCLUSIONS: The average HRQoL in long-term lymphoma survivors seems relatively high, especially when measured by the QLQ-C30. However, subgroup analyses revealed HRQoL was affected by active disease and comorbidities, other than, but perhaps related to, cancer. This has two important implications. Firstly, population-based studies need to incorporate comorbidities to adequately assess and forecast HRQoL in lymphoma survivors. Secondly, in economic evaluations the modelling of cancer free survival needs to be reconsidered since HRQoL in life years gained is affected by comorbidities. Future economic evaluations should incorporate these two implications to obtain more accurate HRQoL estimates.
Conference/Value in Health Info
2011-11, ISPOR Europe 2011, Madrid, Spain
Value in Health, Vol. 14, No. 7 (November 2011)
Code
PCN197
Topic
Methodological & Statistical Research
Topic Subcategory
PRO & Related Methods
Disease
Oncology